BioSpace News Archive

Fact.MR – A Market Research and Competitive Intelligence Provider: Due to rising prevalence of sepsis and the growing burden of various infectious diseases, the global sepsis diagnostics market is showing consistent expansion.

Valneva SE a specialty vaccine company, reported its revenue and cash balance for the full year 2021 and provided full year 2022 revenue guidance.

Sobi plans to publish its report for the fourth quarter and full-year 2021 on 10 February 2022 at 08:00 CET.

Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new and effective treatments for psychiatric and neurological disorders, today announced a new chemical entity (“NCE”) development program and named Massachusetts-based Hooke Laboratories as its research partner.

Mesa Laboratories, Inc. announced results for its third fiscal quarter and nine months ended December 31, 2021.

Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, announced its participation in the Guggenheim Healthcare Talks 2022 Oncology Day.

Pharmazz, Inc. (“Pharmazz”), today announced that it has submitted an Investigational New Drug Application (IND) to the India Central Drugs Standard Control Organization (CDSCO) for a Phase II clinical trial of sovateltide in hypoxic-ischemic encephalopathy (HIE) in neonates.

scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, president & chief executive officer, is scheduled to present at the 11th Annual SVB Leerink Global Healthcare Conference.

Replimune Group Inc., a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, announced financial results for the fiscal third quarter ended December 31, 2021 and provided a business update.

Catalyst Pharmaceuticals, Inc. today reported that the District Court which heard Catalyst’s Lawsuit against the FDA has entered summary judgment in favor of Catalyst.